SANOFI · NSE
Sanofi India Limited
₹3,087.4
+0.08% (+₹2.4)
Prev. close
₹3,085
Volume
12,855
Delivery %
56.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Deepak Arora
Headquarters
Mumbai
Employees
1,097
Exchange
View on NSE ↗Key stats
Market cap
₹7,104.95 Cr
P/E ratio (TTM)
22.1
Dividend yield
7.71%
EPS (TTM)
₹139.44
Beta (1Y · daily vs NIFTY 50)
0.56
Beta (5Y · monthly vs NIFTY 50)
0.71
Shares float
90.72 L
EPS · quarter ended Jun 2026
₹36.26
Financial Performance
01 · Financials
Revenue for Dec 2021–Dec 2021 is as filed with BSE (standalone), and the first plotted growth figure is computed against Dec 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.6% on Dec 2022. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: January–December (calendar year — this company reports on a December year-end), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| ₹2,956.60 Cr | ₹2,770.10 Cr | ₹1,981.60 Cr | ₹2,013.20 Cr | ₹1,823.40 Cr | |
| EBITDA | ₹1,326.10 Cr | ₹907.90 Cr | ₹569.80 Cr | ₹471.10 Cr | ₹483.70 Cr |
| ₹944.40 Cr | ₹620.60 Cr | ₹602.90 Cr | ₹413.50 Cr | ₹326.70 Cr | |
| Diluted EPS | ₹410.06 | ₹269.47 | ₹261.78 | ₹179.46 | ₹141.85 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| ₹2,918.50 Cr | ₹3,061.00 Cr | ₹2,071.70 Cr | ₹1,714.80 Cr | ₹1,611.80 Cr | ₹1,254.80 Cr | |
| ₹22.60 Cr | ₹24.60 Cr | ₹23.60 Cr | ₹19.00 Cr | ₹19.30 Cr | ₹17.80 Cr | |
| Stockholders' equity | ₹2,119.00 Cr | ₹2,225.60 Cr | ₹1,275.80 Cr | ₹1,015.20 Cr | ₹860.60 Cr | ₹749.20 Cr |
Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| — | ₹558.80 Cr | ₹398.70 Cr | ₹230.40 Cr | ₹461.50 Cr | ₹438.30 Cr | |
| Investing cash flow | — | ₹630.80 Cr | ₹650.90 Cr | ₹37.50 Cr | ₹-19.20 Cr | ₹-11.30 Cr |
| — | ₹-849.00 Cr | ₹-1,582.70 Cr | ₹-878.30 Cr | ₹-392.40 Cr | — | |
| Capital expenditure | — | ₹-23.00 Cr | ₹-22.20 Cr | ₹-34.30 Cr | ₹-36.40 Cr | ₹-25.70 Cr |
| End cash position | ₹1,197.40 Cr | ₹1,538.00 Cr | ₹1,004.90 Cr | ₹394.50 Cr | ₹283.80 Cr | ₹262.90 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 60.40% |
| Public | 39.60% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Sanofi India Limited | ₹7,117.61 Cr | ₹3,085 | 22.0 | 9.50 | 43.6% | 0.02 | -8.3% | -38.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.